Our mission as a lab devoted to neuropsychopharmacology research is to decipher mechanisms of susceptibility and resilience during sensitive developmental windows preceding adolescence in order to contribute to buck the trend in current youth mental health.

The research activities currently funded and carried out in the Melis lab are the followings:

  1. Maternal THC Effects on Reward and Neuronal Activity and function (MaTERNA) -(funded by RO1DA044925-01A1-NIDA; FISR2019_00202- MUR; Cariplo 2022_1619) (PI)
  2. Synaptic Adaptations Following Early life Traumas (SAFETy) -(funded by Regione Autonoma Sardegna: RASSR32909-RAS2017; and Université Franco-Italienne: G20_525-UFI) (PI)
  3. Caratterizzazione delle proprietà specifiche dell’acido linoleico coniugato (CLA) in forma fosfolipidica per il trattamento di patologie psichiatriche a base neuroinfiammatoria e individuazione di biomarcatori dell’efficacia terapeutica -(PoC-MIUR; POC01_00069) (Co-PI)
  4. Targeting neurosteroids for neuroprotection in Parkinson’s disease (FdS) (Co-PI)
  5. Neurosteroids as a novel predictive biomarker associated with sleep disorders in PD (FdS; F71I17000200002) (Co-PI)

All of these are carried out in my lab @ Division of Neuroscience and Clinical Pharmacology of the DiSB in collaboration with local, national and international partners such as:

MaTERNA team (2019): left-to-right sitting, Mauro, Francesco, Valeria, Miriam, Roberto; left-to-right standing, Paola, Claudia, Pierluigi.